WASHINGTON — The Senate on Thursday easily passed legislation that aims to help terminally ill patients access experimental treatments under so-called “right to try” laws.

The legislation, from Sen. Ron Johnson (R-Wis.), would keep the federal government, including the Food and Drug Administration, from interfering when a terminally ill patient seeks access to experimental treatments that haven’t yet received FDA approval, subject to several specific conditions. It is an updated version of a January bill Johnson reintroduced after making the issue a priority on the campaign trail last year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • As a practical matter it is impossible to prevent the data from Right to Try from negatively biasing future clinical trials. Anybody debating whether to enroll can submit an expedited FOIA request to find out how many folks have been treated and with what outcomes.

    Another significant issue is that many of these drugs have failed controlled clinical trials but there is still a limited drug supply left that is ultimately destined for the the incinerator. To keep this drug around, ensure stability, then deal with all of the logistics to get in the hands of a few patients? Facing such strictures many companies will say no. It doesn’t make them bad people, just a business decision.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy